Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells

Blood

Volumn 86, Issue 1, 1995, Pages 381-389

  Gazitt, Yair ^a   Reading, Chris C ^b   Hoffman, Ron ^b   Wickrema, Amittha ^b   Vesole, David H ^b   Jagannath, Sundar ^b   Condino, Janet ^b   Lee, Brenda ^b   Barlogie, Bart ^b   Tricot, Guido ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CD56 ANTIGEN; CYCLOPHOSPHAMIDE; DNA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PHENYLALANINE METHYL ESTER; PROPIDIUM IODIDE;

ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LYMPHOCYTE DEPLETION; LYMPHOCYTE SUBPOPULATION; MULTIPLE MYELOMA; MYELOMA CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029045433     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v86.1.381.bloodjournal861381     Document Type: Article

References (64)

1. Jagannath S, Vesole D, Glenn L, Crowley J, Barlogie B: Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood cell support. Blood 80:1666, 1992
2. Attal M, Huguet F, Schleifer D, Payen C, Laroche M, Fournie B, Maziere B, Pris J, Lament G: Intensive combined therapy for previously untreated aggressive myeloma. Blood 79:1130, 1992
3. Fermand J, Chervet S, Ravaud P, Divine M, Leblond V, Dreyfus F, Mariette X, Bruet J-C: High dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma. Blood 82:2005, 1993
4. Gore ME, Viner C, Meldrum M, Bell J, Milan S, Zuiable A, Slevin M, Selby PJ, Clark PI, Millar B, Maitland JA, Judson ER, Tillyer C, Malpas JS, McElwain TJ: Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 2:879, 1989
5. Harousseau JL, Milpied N, Laporte JP, Collombat P, Facon T, Tigaud JD, Casassus P, Guipot F, Ifrah N, Gandhour C: Double-intensive therapy in high-risk multiple myeloma. Blood 79:2827, 1992
6. Dimopolous M, Alexanian R, Przepiorka D, Hester J, Andersson B, Giralt S, Mehra R, van Besien K, Delasalle KB, Reading C, Deisseroth AB, Champlin RE: Thiotepa, busulfan, and cyclophosphamide: A new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood 82:2324,1993
7. Barlogie B, Jagannath S, Vesole D, Tricot G, Naucke S, Copland M, Crowley J: Total therapy for newly diagnosed multiple myeloma. Blood 82:198a, 1993 (abstr, suppl)
8. Bik To L, Shepperd KM, Haylock DM, Dyson PG, Charles P, Thorp DL, Dale BM, Dart GW, Roberts MM, Sage RE, Juttner CA: Single high dose of cyclophosphamide enable the collection of high numbers of hematopoietic stem cells from peripheral blood. Exp Hematol 18:442, 1990
9. Hass R, Dick Ho A, Bredthauer U, Cayeux S, Egerer G, Knauf W, Hunstein W: Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony stimulating factor. Exp Hematol 18:94, 1990
10. Sheridan WP, Begley CG, Juttner CA, Szer J, Bik To L, Maher D, McGrath KM, Morstyn G, Fox RM: Effect of peripheral blood progenitor cells mobilized by filgrastin (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 339:640, 1992
11. Kotasek D, Shepherd KM, Sage RE, Dale BM, Norman JE, Charles P, Gregg A, Pillow A, Bolton A: Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 9:11,1992
12. Gianni AM, Siena S, Bregni M, Tarella C, Stern AC, Pileri A, Bonadonna G: Granulocyte-macrophage colony-stimulating factor to harvest circulating hematopoietic stem cells for autotransplantation. Lancet 2:580, 1989
13. Teshima T, Harada M, Takamatsu Y, Makino K, Inaba S, Akashi K, Kondo S, Tanaka T, Ishi E, Niho Y: Granulocyte colony-stimulating factor (G-CSF)-induced mobilization of cirulating hematopoietic stem cells. Br J Hematol 84:570, 1993
14. Vesole D, Barlogie B, Jagannath S, Cheson B, Tricot G, Crowley J: High-dose therapy for multiple myeloma: Improved prognosis with better supportive care and double transplant. Blood 84:950, 1994
15. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet G, Rossi JF, Casassus P, Thyss A, Maisonneuve, Facon T, Ifrah N, Paven C, Bataille R: High dose therapy in multiple myeloma: A prospective randomized study of the "Intergroupe Francais Du Myelome" (IFM). Blood 84:386a, 1994 (abstr, suppl 1)
16. Abdou NI, Abdou NL: The monoclonal nature of lymphocytes in multiple myeloma. Ann Intern Med 83:42, 1975
17. Mellstedt H, Hammarstrom S, Holm G: Monoclonal lymphocyte population in human plasma cell myeloma. Clin Exp Immunol 17:371, 1974
18. Bast E, Van Camp B, Reynaert P, Wiringa G, Ballieux R: Idiotypic peripheral blood lymphocytes in monoclonal gammopathy. Clin Exp Immunol 47:682, 1982
19. Carmagnola AL, Boccadoro M, Massaia M, Pileri A: The idiotypic specificities of lymphocytes in human monoclonal gammopathies: Analysis with the fluorescence activated cell sorter. Clin Exp Immunol 51:173, 1983
20. Berenson J, Wong R, Kim K, Brown N, Lichtenstein A: Evidence for peripheral blood B lymphocyte, but not T lymphocyte involvement in multiple myeloma. Blood 70:1550, 1987
21. + monoclonal B-lineage cells in peripheral blood from myeloma patients as late stage B cells. Blood 78:711, 1991
22. Pilarksi LM, Jensen GS: Monoclonal circulating B cells in multiple myeloma. Hematol/Oncol Clin N Am 6:297, 1992
23. Harada H, Kawano MM, Huang M, Harada Y, Iwato K, Tanabe O, Tanaka H, Sakai H, Kuramoto A: Phenotypic differentiation of plasma cells from mature myeloma cells. Blood 81:2658, 1993
24. Pilarski LM, Belch AR: Circulating monoclonal B cells expressing p glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma. Blood 83:724, 1994
25. + cells present in autologous transplants of CML contribute to relapse after ABMT in CML. Blood 83:3068, 1994
26. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J, Anderson WF, Ihle JN: Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 341:85, 1993
27. Sharp JG, Joshi SS, Armitage JO, Bierman P, Coccia PF, Harrington DS, Kessinger A, Crouse DA, Mann SL, Weisenburger DD: Significance of detection of occult non-Hodgkin's lymphoma in histologically uninvolved bone marrow by a culture technique. Blood 79:1074, 1992
28. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, Grossbard ML, Rabinowe SN, Coral F, Freeman GJ, Ritz J, Nadler LM: Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Eng J Med 325:1525, 1991
29. Moss TJ, Cairo M, Santana VM, Weinthal J, Hurvitz C, Bostrom M: Clonogenic circulating BM cells: Implications regarding peripheral stem cell transplantation. Blood 83:3085, 1994
30. Gazitt Y, Cantor A, He Y-J, Koza S, Cohen RJ, GrahamPole J: Prognostic factors in purged marrow from patients with neuroblastoma receiving myeloablative treatment: Tumor cell number, N-myc protein, N-myc gene amplification and rate of hematologic recovery. Int J Oncol 3:755, 1993
31. Shpall EJ, Bast RC, Joines WT, Jones RB, Anderson I, Johnston C, Egglestone S, Tepperberg M, Edwards S, Peters WP: Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation. Bone Marrow Transplant 7:145, 1991
32. Baum CM, Weissman IL, Tsukamoto AS, Buckle A-M, Peault B: Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci USA 89:2804, 1992
33. Udomsakdi C, Lansdorp PM, Hogge DE, Reid DS, Eaves AC, Eaves CJ: Characterization of primitive hematopoietic cells in normal human peripheral blood. Blood 80:2513, 1992
34. - bone marrow cells contain progenitor cells capable of self-renewal, multilineage differentiation, and long-term in vitro hematopoiesis. Blood Cells 17:287, 1991
35. Kyoizumi S, Baum CM, Kaneshima H, McCune JM, Yee EJ, Namikawa, R: Implantation and maintenance of functional human bone marrow in SCID-hu mice. Blood 79:1704, 1992
36. + precursor cells. J Exp Med 174:1283, 1991
37. Craig W, Kay R, Cutler RL, Lansdorp PM: Expression of Thy-1 on human hematopoietic progenitor cells. J Exp Med 177:1331, 1993
38. Billadeau D, Blackstadt M, Greipp P, Kyle RA, Oken MM, Kay N, Van Ness B: Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: A technique for sequential quantitation of residual disease. Blood 78:3021, 1991
39. Jonsson OG, Kitchens RL, Scott FC, Smith RG: Detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin hypervariable region specific oligonucleotide probes. Blood 76:2072, 1990
40. Brisco MJ, Tan LW, Orsborn AM, Morley AA: Development of a highly sensitive assay, based on the polymerase chain reaction, for rare B-lymphocyte clones in a polyclonal population. Br J Haematol 75:163, 1990
41. Nizet Y, Martial P, Vaerman JL, Philippe M, Wildmann C, Staelens JP, Cornu G, Ferrant A, Michaux JL, Sokal G: Follow-up of residual disease (MRD) in B lineage acute leukaemias using a simplified PCR strategy: Evolution of MRD rather than its detection is correlated with clinical outcome. Br J Hematol 79:205, 1991
42. Billadeau D, Quam L, Thomas W, Kay N, Greipp P, Kyle R, Oken MM, Van Ness B: Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood 80:1818, 1992
43. Hata H, Xiao H, Petrucci MT, Woodliff J, Chang R, Epstein J: Interleukin-6 gene expression in multiple myeloma: A characteristic of immature tumor cells. Blood 81:3357, 1993
44. Takaue Y, Roome AJ, Turpin JA, Reading CL: Depletion of T- cells from bone marrow by the use of counter flow centrifugal elutriation. Am J Hematol 23:247, 1986
45. Law P, Schwatrz GN, Alsop T, Haiber LM, Smith DM, Dooley DC: Removal of peripheral blood monocytes by phenylalanine methyl ester has no effect on colony growth of hematopoietic progenitors. Int J Cell Clone 7:100, 1989
46. Billadeau D, Ahmann G, Greipp P, Van Ness B: The bone marrow of MM patients contains B cell populations at different stages of differentiation that are clonally related to the malignant clone. J Exp Med 178:1023, 1993
47. Maniatis T, Fritsch EF, Sambrook J (eds): Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY, Cold Spring Harbor Press, 1982
48. Ravetch JV, Siebenlist U, Korsmeyer S, Waldmann T, Leder P: Structure of the human mu locus: Characterization of embryonic and rearranged J and D genes. Cell 27:582, 1981
49. Rosenfeld CJ Evans C, Shadduck RK: Human macrophage stimulating factor induces macrophage colonies after PME treatment of human marrow. Blood 76:1783, 1990
50. Reading C, Tricot G, Dietz I, Schwartz D, Young J, Chen S, Feng L, Brown W, Hoffman R: Evaluation of in vivo and in vitro assays of human stem cells. Exp Hematol 22:786, 1994
51. + marrow and/or peripheral blood progenitor cells into patients with breast cancer or NHL after high dose chemotherapy. Exp Hematol 22:774, 1994
52. Heimfeld S, Fogartz B, McGuire K, Williams S, Berensen RJ: Peripheral blood stem cell mobilization after stem cell factor or G-CSF treatment. Rapid enrichment for stem cells and progenitor cells using separate immunoaffinity separation system. J Clin Oncol 6:1368, 1988
53. + cells isolated with the Baxter Isolex 500. Exp Hematol 22:775, 1994
54. + cells from peripheral blood of autologous transplant patients. Blood 80:527a, 1992 (abstr, suppl)
55. Takishita M, Kosaka M, Goto T, Saito S: Cellular origin and extent of clonal involvement in multiple myeloma: Genetic and phenotypic studies. Br J Haematol 87:735, 1994
56. + B-cells in the blood of patients with MM myeloma express clonogenic IgH sequences. Blood 84:385a, 1994 (abstr, suppl)
57. Bergsagel PL, Belch AR, Pilarski LM: The blood B-cells and bone marrow plasma cells in a patient with multiple myeloma include cells with the same N-ras mutation. Blood 84:524a, 1994 (abstr, suppl)
58. Jelinek DF, Ahmann GJ, Greipp PR, Jalal SM, Westendorf JJ, Katzman JA, Kyle RA, Lust JA: Coexistent of aneuploid myeloma cell line that exhibit clonal immunoglobulin gene rearrangement: Clinical implications. Cancer Res 53:5320, 1993
59. - stem cells from mobilized peripheral blood by high speed fluorescence activated cell sorting for use as an autograft for multiple myeloma patients. Blood 84:399a, 1994 (abstr, suppl)
60. + positive peripheral blood progenitors and growth factors on engraftment. J Clin Oncol 12:28, 1994
61. + cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin. Blood 84:1421, 1994
62. - subpopulation from mobilized peripheral blood. Blood 85:368, 1995
63. Gazitt Y, Reading C, Lee J-H, Barlogie B, Vesole D, Jagannath S, Simonetti D, DiGiusto R, Schnell J, Rosen NR, Tricot G: Differential peripheral blood mobilization of tumor and normal hematopoietic progenitor cells in multiple myeloma. Blood 84:354a, 1994 (abstr, suppl 1)
64. Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L, Cheson B, Crowley J, Barlogie B: Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients. Blood 85:588, 1995